Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Elocta

- PMLiVE

Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

The rare bleeding disorder affects approximately 800,000 people globally

- PMLiVE

Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

- PMLiVE

Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

- PMLiVE

Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B

More than 11,800 people were living with the genetic blood disorders in the UK in 2023/2024

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark

The site will be designed to accommodate multiple product types within rare diseases

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

The rare bleeding disorder affects approximately 1,125,000 people globally

- PMLiVE

Pfizer’s Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients

More than 800,000 people globally are affected by the genetic blood disorder

- PMLiVE

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.

Petauri Evidence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links